undamentalytics Newsletter
Sign in

Cytek Biosciences, Inc. (CTKB) stock

Add to watchlist

Add holding +

NASDAQ: CTKB Nasdaq Life Sciences Tools & Services Next results ~November 4, 2026

C Fundamentals grade

Cytek Biosciences, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$2.3

Valuation models combined (3)

Base case. Range ~$1.7–$5.1. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Cytek Biosciences, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds72 adding, 101 cuttingOf 36 active managers that changed their stake, 28 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cytek Biosciences files

Where Cytek Biosciences stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $207m, up 5.4% on a year earlier, faster than the 3.6% growth a quarter earlier. Free-cash-flow margin fell to -5.9% from 5.5% a year earlier. Operating margin narrowed to -21.6% from -13.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 3 financial-health checks. Our revenue-to-maturity cash-flow model value is $1.70 a share, against a share price of $6.13.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Cytek Biosciences, Inc.'s trailing-twelve-month revenue grew 5.4% year on year, with a free-cash-flow margin of -5.9%. Where it lags: days sales outstanding of 88 days ranks 43 of 48 life sciences tools & services companies we cover.

Current signal Net margin compressing: TTM net margin fell to -39.0%, down 35.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Loss-making. Operating margin is -21.6%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 7.9 points on a year ago.
  • Burning cash. Free cash flow was -5.9% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 56% and a beta of 0.9 against the S&P 500.
  • Below peers: days sales outstanding. Days sales outstanding of 88 days ranks 43 of 48 life sciences tools & services companies we cover (median 62 days).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 4 of the last four quarters.

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.03 against an average estimate of -$0.02: missed by 55.0%
Revenue
$48m, up 5.6% on a year earlier
Share reaction
-2.8% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
total revenue $207m to $212m (full year 2026)
Next report
November 4, 2026

Cytek Biosciences' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+3.2%
  • 1 week-0.4%
  • 1 month+1.4%
  • This year+14.3%
  • 1 year+51.1%
  • 5 years-75.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$207M
Operating margin
-21.6%
Net margin
-39.0%
EPS (TTM, diluted)
$-0.63

Growth

Revenue growth
+5.4%
Change in growth rate
+1.8 pts
Share count change
−0.3%

Cash

Free cash flow (TTM)
-$12.2M
FCF margin
-5.9%
Stock pay % of revenue
10.3%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Governance
  2. Announcement
  3. Results
  4. Guidance
  5. Leadership

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cytek Biosciences, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Cytek Biosciences, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.11 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$1.9 ~$1.3–$2.3 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$5.1 ~$4.1–$12 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$1.7 ~$1.4–$2.1 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$2.3 ~$1.7–$5.1 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cytek Biosciences, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$16.32$10.21$9.12$6.49$5.05$5.77
Market value$1.3bn$1.4bn$1.2bn$848m$645m$741m
+ Net debt (− = net cash)−$365m−$294m−$166m−$98m−$90m−$74m
Enterprise value$966m$1.1bn$1.1bn$750m$555m$668m
Multiples
Price / sales 10.4x8.6x6.4x4.2x3.2x3.6x
Price / earnings n/mn/m————
Price / free cash flow n/m—n/m38.8x——
EV / EBITDA 92.9xn/m————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

36 /100

Weak moat

How hard Cytek Biosciences's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median 2.0% of total assets over 5 years.

  • Pricing power 18 / 20

    Gross margin has been a median 57.5%, moving by 3.6 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -12.2%; its worst year was -21.6%.

  • Cash conversion 5 / 20

    Free cash flow was positive in 3 of 6 years, at a median -0.2% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (41 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $53m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.34 +34% $209m +4%
Next −$0.25 +26% $223m +7%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −1.9% on 90 days ago. In the last 30 days, 0 analysts raised Cytek Biosciences, Inc.'s forecast and 2 cut it.

Consensus EPS forecast Cytek Biosciences, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.35 Current fiscal year, 60 days ago: −$0.34 Current fiscal year, 30 days ago: −$0.34 Current fiscal year, 7 days ago: −$0.34 Current fiscal year, Now: −$0.34 −$0.34 Next fiscal year, 90 days ago: −$0.27 Next fiscal year, 60 days ago: −$0.25 Next fiscal year, 30 days ago: −$0.25 Next fiscal year, 7 days ago: −$0.25 Next fiscal year, Now: −$0.25 −$0.25

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.35−$0.27
60 days ago −$0.34−$0.25
30 days ago −$0.34−$0.25
7 days ago −$0.34−$0.25
Now −$0.34−$0.25

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.02 −$0.03 −55.0%
Mar 2026 −$0.08 −$0.10 −20.0%
Dec 2025 $0.01 −$0.29 −2014.7%
Sept 2025 $0.01 −$0.00 −103.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • total revenue full year 2026 $207m to $212m Raised
    “Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million, assuming no change in current foreign currency exchange rates.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

3 analysts, Oct 2026
Buy267%
Hold133%
Sell00%

Monthly trend

  1. Oct 20261113
  2. Sep 20261124
  3. Aug 20261124
  4. Jul 20261124

Counts of recommendations published by analysts covering Cytek Biosciences, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
4.3%
of tradable shares
Days to cover
2.67
at average volume
Short interest, 1 month
−16%
to October 15, 2026
Held by institutions
63%
of shares
Held by insiders
8.5%
of shares
Employees
682
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +47.9%

$3.90 on October 31, 2025 to $5.77

ThenNowEffect
Revenue (last 12 months) $196m $207m +5.4%
P/S multiple 2.6x 3.6x +39.9%
Share count 129m 128m +0.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +31.4%

$4.39 on November 3, 2023 to $5.77

ThenNowEffect
Revenue (last 12 months) $176m $207m +17.7%
P/S multiple 3.5x 3.6x +2.9%
Share count 139m 128m +8.5%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
CTKB−37%−11%−29%−22%+14%
Industry peers (median)−53%−3%−13%−2%+16%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
CTKB42%50%25%42%46%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
CTKB−57%−70%−49%−67%−42%
S&P 500−25%−10%−8%−19%−9%

Worst fall since July 23, 2021: 91% from September 15, 2021 to May 23, 2025. Getting back needed a 1054% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.35 – $6.30
From 52-week high
−8.4%
vs 50-day average
+8.9%
vs 200-day average
+24.0%
Volatility (1 year)
56%
Beta vs S&P 500
0.87

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±12.7%
After a week
5 up, 7 down
typical move ±15.7%
After a month
4 up, 8 down
typical move ±15.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −2.8% −0.4% +11.7% +9.8%
May 7, 2026 −6.7% +0.5% −32.1% −18.2%
February 26, 2026 +2.5% −1.0% +0.2% −1.1%
January 13, 2026 −4.1% −0.7% −4.8% −28.1%
November 5, 2025 +16.1% −0.7% +23.0% +27.6%
August 6, 2025 +5.9% +0.7% +7.5% +3.6%
May 8, 2025 −21.6% +0.6% −28.2% −4.6%
February 27, 2025 −10.2% −0.1% −10.8% −20.0%
January 15, 2025 −24.4% +1.6% −21.6% −28.0%
November 5, 2024 +42.3% +3.7% +35.4% +25.8%
August 6, 2024 −12.7% +0.2% −8.2% −6.7%
May 8, 2024 −2.8% +0.6% −4.4% −6.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Cytek Biosciences, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cytek Biosciences, Inc.
$180M $190M $200M $210M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $183.1M Revenue (TTM), FY23 Q4: $193M Revenue (TTM), FY24 Q1: $200.8M Revenue (TTM), FY24 Q2: $197.7M Revenue (TTM), FY24 Q3: $201.2M Revenue (TTM), FY24 Q4: $200.5M Revenue (TTM), FY25 Q1: $197.1M Revenue (TTM), FY25 Q2: $196M Revenue (TTM), FY25 Q3: $196.8M Revenue (TTM), FY25 Q4: $201.5M Revenue (TTM), FY26 Q1: $204.2M Revenue (TTM), FY26 Q2: $206.7M $206.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $183.1M
FY23 Q4 $193M
FY24 Q1 $200.8M
FY24 Q2 $197.7M
FY24 Q3 $201.2M
FY24 Q4 $200.5M
FY25 Q1 $197.1M
FY25 Q2 $196M
FY25 Q3 $196.8M
FY25 Q4 $201.5M
FY26 Q1 $204.2M
FY26 Q2 $206.7M
Revenue growth, TTM YoY Cytek Biosciences, Inc.
-10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 18.5% Revenue growth, TTM YoY, FY23 Q4: 17.7% Revenue growth, TTM YoY, FY24 Q1: 20.9% Revenue growth, TTM YoY, FY24 Q2: 12.6% Revenue growth, TTM YoY, FY24 Q3: 9.9% Revenue growth, TTM YoY, FY24 Q4: 3.9% Revenue growth, TTM YoY, FY25 Q1: -1.9% Revenue growth, TTM YoY, FY25 Q2: -0.8% Revenue growth, TTM YoY, FY25 Q3: -2.2% Revenue growth, TTM YoY, FY25 Q4: 0.5% Revenue growth, TTM YoY, FY26 Q1: 3.6% Revenue growth, TTM YoY, FY26 Q2: 5.4% 5.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 18.5%
FY23 Q4 17.7%
FY24 Q1 20.9%
FY24 Q2 12.6%
FY24 Q3 9.9%
FY24 Q4 3.9%
FY25 Q1 -1.9%
FY25 Q2 -0.8%
FY25 Q3 -2.2%
FY25 Q4 0.5%
FY26 Q1 3.6%
FY26 Q2 5.4%
Operating margin (TTM) Cytek Biosciences, Inc.
-30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -15.1% Operating margin (TTM), FY23 Q4: -14.4% Operating margin (TTM), FY24 Q1: -13.2% Operating margin (TTM), FY24 Q2: -13.1% Operating margin (TTM), FY24 Q3: -11.8% Operating margin (TTM), FY24 Q4: -10.2% Operating margin (TTM), FY25 Q1: -12.6% Operating margin (TTM), FY25 Q2: -13.7% Operating margin (TTM), FY25 Q3: -16.2% Operating margin (TTM), FY25 Q4: -20.0% Operating margin (TTM), FY26 Q1: -21.5% Operating margin (TTM), FY26 Q2: -21.6% -21.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -15.1%
FY23 Q4 -14.4%
FY24 Q1 -13.2%
FY24 Q2 -13.1%
FY24 Q3 -11.8%
FY24 Q4 -10.2%
FY25 Q1 -12.6%
FY25 Q2 -13.7%
FY25 Q3 -16.2%
FY25 Q4 -20.0%
FY26 Q1 -21.5%
FY26 Q2 -21.6%
FCF margin (TTM) Cytek Biosciences, Inc.
-10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -4.3% FCF margin (TTM), FY23 Q4: 0.2% FCF margin (TTM), FY24 Q1: 0.7% FCF margin (TTM), FY24 Q2: 5.4% FCF margin (TTM), FY24 Q3: 14.2% FCF margin (TTM), FY24 Q4: 10.8% FCF margin (TTM), FY25 Q1: 8.8% FCF margin (TTM), FY25 Q2: 5.5% FCF margin (TTM), FY25 Q3: -3.0% FCF margin (TTM), FY25 Q4: -4.4% FCF margin (TTM), FY26 Q1: -6.3% FCF margin (TTM), FY26 Q2: -5.9% -5.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -4.3%
FY23 Q4 0.2%
FY24 Q1 0.7%
FY24 Q2 5.4%
FY24 Q3 14.2%
FY24 Q4 10.8%
FY25 Q1 8.8%
FY25 Q2 5.5%
FY25 Q3 -3.0%
FY25 Q4 -4.4%
FY26 Q1 -6.3%
FY26 Q2 -5.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 93 128 164 193 200 201 207
Gross profit 52 79 101 109 111 104 110
EBITDA 14 10 1 −22 −13 −33 −39
Operating income 14 9 −2 −28 −21 −40 −45
Net income 19 3 2 −12 −6 −67 −81
Diluted EPS $0.10 $0.00 $0.02 −$0.09 — — −$0.63
Growth (year on year)
Revenue — +37.8% +28.2% +17.7% +3.9% +0.5% +5.4%
EBITDA — −27.1% −93.4% — — — —
Operating income — −33.0% −119.7% — — — —
Net income — −84.4% −17.9% — — — —
Diluted EPS — −100.0% — — — — —
Margins
Gross margin 55.7% 61.9% 61.6% 56.7% 55.4% 51.8% 53.2%
EBITDA margin 15.4% 8.1% 0.4% −11.3% −6.6% −16.3% −18.8%
Operating margin 14.7% 7.2% −1.1% −14.4% −10.2% −20.0% −21.6%
Net margin 20.9% 2.4% 1.5% −6.3% −3.0% −33.0% −39.0%
Free-cash-flow margin 14.7% 0.2% −13.4% 0.3% 10.9% −4.4% −5.8%
Cash flow
Cash from operations 15 5 −12 5 25 −5 −6
Capital spending 2 4 10 5 4 4 6
Free cash flow 14 0 −22 1 22 −9 −12
Stock-based pay 1 7 17 22 27 25 21
Free cash flow after stock pay 13 −6 −39 −21 −5 −33 −33
Balance sheet
Cash 165 365 297 167 99 91 74
Total debt 0 0 2 2 1 1 0
Net debt (negative = net cash) −165 −365 −294 −166 −98 −90 −74
Diluted shares 33m 82m 139m 135m 131m 128m 128m
Returned to shareholders
Buybacks — 0 0 44 22 15 −0
Total returned — 0 0 44 22 15 −0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $447m
Short-term assets $378mLonger-term assets $69m
What it owes, and who funded it · $447m
Short-term liabilities $84mLonger-term liabilities $41mShareholders' equity $322m
  • Short-term assets cover short-term liabilities $378m of assets due within a year against $84m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $378m short-term assets against $41m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$45m against $312,000 of interest.

From Cytek Biosciences, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
-$63,000
Returned to shareholders
1%
of free cash flow
Buybacks, last 3 fiscal years
$80.8M
Diluted share count
−0.3%
year over year
Total shareholder yield
-0.0%
dividends 0.0% + buybacks -0.0% of market value
R&D spending
18.0%
of revenue
Days sales outstanding
88 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated CTKB MRVI CYRX MLAB GRAL SDGR Median
Revenue, last 12 months $207m $209m $186m $250m $165m $259m $229m
Revenue growth, last 12 months 5.4% −5.0% 12.1% 3.0% 23.1% 8.9% 6.9%
Revenue growth, 3-year average 5.6% −27.3% −8.2% 4.4% — 10.2% 2.9%
Revenue growth, latest quarter 5.6% 8.5% 7.7% 1.0% 25.7% 7.5% 8.5%
Gross margin 53.2% 34.9% 47.1% 64.2% — 56.9% 51.9%
Operating margin −21.6% −56.1% −21.2% 9.0% −338.4% −59.2% −14.3%
Operating margin, 3-year average −16.1% −73.7% −60.1% −34.7% <−999% −81.0% −22.4%
Net margin −39.0% −37.1% −20.1% 1.9% −236.9% −21.0% −16.1%
Cash from operations / revenue −2.9% −12.1% 4.3% 22.3% −178.4% −49.0% 1.3%
Free-cash-flow margin −5.9% −17.2% −10.8% 21.2% −179.2% −50.3% −2.2%
Free-cash-flow margin, 3-year average 1.7% −14.3% −22.6% 17.9% — −45.4% 0.6%
Stock pay / revenue 10.3% 14.3% 5.2% 6.5% 38.9% 14.9% 4.4%
Change in share count −0.3% 2.3% 0.6% 3.0% 18.5% 1.7% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 5.4% 6.9% 33 of 54
Change in growth rate Growth +1.8pp +0.4pp 18 of 54
Gross margin Profitability 53.2% 52.0% 21 of 45
Operating margin Profitability -21.6% -14.3% 30 of 52
Net margin Profitability -39.0% -12.2% 38 of 54
Free-cash-flow margin Cash generation -5.9% -1.3% 30 of 54
Stock pay as % of revenue Cash generation 10.3% 4.4% 34 of 53
Change in share count Balance sheet -0.3% 1.0% 18 of 46
Days sales outstanding Balance sheet 88 days 62 days 43 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $144M 71.6% ▼ 5.9%
Services $57.3M 28.4% ▲ 21.3%
Geography
Region Revenue YoY
United States $95.3M ▲ 2.9%
EMEA $55.9M ▼ 10.4%
Asia Pacific $41.1M ▲ 14.8%
China $20.5M —
Other $9.3M ▼ 4.6%

These categories overlap or exclude eliminations, so shares aren't shown.

From Cytek Biosciences, Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$361M
Institutions reporting
153
Shares held vs prior quarter
▼ 4.2%
Positions opened / closed
28 / 37

Top buyers and sellers, Q2 2026: 72 institutions bought and 101 sold ; the biggest buyer was Millennium Management LLC (+3.0M shares) and the biggest seller Blackrock, Inc (−7.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $42.4M 9.6M 11.8% ▼ 43.7%
Millennium Management LLC $41.4M 9.3M 11.5% ▲ 48.4%
Boston Partners $33.9M 7.7M 9.4% ▲ 32.0%
Hhlr Advisors, Ltd. $29.5M 6.7M 8.2% 0.0%
Topline Capital Management, LLC $27.8M 6.3M 7.7% ▼ 11.1%
Vanguard Capital Management LLC $21.9M 4.9M 6.1% ▲ 3.7%
Geode Capital Management, LLC $13.6M 3.1M 3.8% ▲ 8.0%
Dimensional Fund Advisors LP $11.6M 2.6M 3.2% ▼ 1.8%
State Street Corp $11.4M 2.6M 3.1% ▼ 37.8%
Goldman Sachs Group Inc $9.6M 2.2M 2.7% ▼ 7.6%
Royce & Associates LP $9.2M 2.1M 2.6% ▲ 26.7%
Russell Investments Group, Ltd. $6.7M 1.5M 1.9% ▲ 11.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cytek Biosciences, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 14, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 7, 2026
  • February 26, 2026
  • January 13, 2026
  • November 5, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Cytek Biosciences, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cytek Biosciences, Inc. in brief

What does Cytek Biosciences, Inc. do?
Cytek Biosciences, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Cytek Biosciences, Inc.'s stock ticker?
Cytek Biosciences, Inc. trades under the ticker CTKB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cytek Biosciences, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cytek Biosciences, Inc. reported revenue of $207M, 5.4% higher than a year earlier, according to its SEC filings.
What is Cytek Biosciences, Inc.'s free cash flow?
Cytek Biosciences, Inc.'s free-cash-flow margin is -5.9% of revenue over the trailing twelve months, ranking 30 of the 54 life sciences tools & services companies we cover.
Who are Cytek Biosciences, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Millennium Management LLC and Boston Partners. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Cytek Biosciences, Inc. buying back stock, and does it pay a dividend?
Cytek Biosciences, Inc. spent -$63,000 on share repurchases over the trailing twelve months, and its diluted share count fell 0.3% over the year.
What is Cytek Biosciences, Inc.'s market cap?
On November 2, 2026, Cytek Biosciences, Inc.'s market capitalisation was about $741M and net debt of -$73.6M. Market figures come from third-party market data and may be delayed.
Who are Cytek Biosciences, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Cytek Biosciences, Inc. are Maravai Lifesciences Holdings, Inc., Cryoport, Inc., Mesa Laboratories Inc, Grail, Inc. and Schrodinger, Inc. The side-by-side comparison below sets their revenue, margins and growth against Cytek Biosciences, Inc.'s.
When is Cytek Biosciences, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cytek Biosciences, Inc. announces its own schedule.